Rubicon Research Limited RUBICON NSEPHARMA
Company Overview
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.
Why Investors Should Care
Generates a return on equity of 19.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 23.6%.
Net profit has compounded at 38.2% per year over the last five years.
Revenue has grown at a 36.6% CAGR over the past five years.
Operating margin of 21.3% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.24.
Recent Developments
- Mar 2026 Revenue of ₹1,731.17 Cr (+36.6% YoY); net profit ₹246.74 Cr.
- Trailing 12 Months Year-on-year growth — revenue +51.6%, earnings +82.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 36.6%, profit CAGR 38.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 36.62% |
| 1 Year: | 51.60% |
Compounded Profit Growth
| 5 Years: | 38.17% |
| 1 Year: | 82.10% |
Stock Price Performance
| 1 Year: | +130.81% |
| 6 Months: | +54.46% |
| 3 Months: | -4.95% |
| 1 Month: | -16.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)27.72 · Oversold
P/E of 83.44 is above the sector median of 36.43 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 23.6%.
- Compounding revenue at 36.6% over 5 years.
- Profit CAGR of 38.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 83.4.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RUBICON Rubicon Research Limited NSEPHARMA | 1,448.50 | 83.44 | ₹23,978.34 Cr | 0.10% | 23.58% | 19.14% | 36.62% | 38.17% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 296.00 Cr | - | 358.15 Cr | 352.49 Cr | 412.00 Cr | 475.53 Cr | 513.91 Cr | 534.34 Cr |
| Cost of Revenue | - | - | 111.59 Cr | 102.93 Cr | - | 157.26 Cr | 169.31 Cr | 168.97 Cr |
| Gross Profit | - | - | 246.55 Cr | 249.56 Cr | - | 318.27 Cr | 344.61 Cr | 365.37 Cr |
| Operating Expenses | 234.00 Cr | - | 183.74 Cr | 180.03 Cr | 318.00 Cr | 221.70 Cr | 238.17 Cr | 251.39 Cr |
| Operating Income | 54.00 Cr | - | 62.81 Cr | 69.54 Cr | 82.00 Cr | 96.57 Cr | 106.44 Cr | 113.98 Cr |
| EBITDA | 62.00 Cr | - | 72.57 Cr | 79.74 Cr | 94.00 Cr | 111.91 Cr | 121.31 Cr | 134.80 Cr |
| Interest Expense | 7.00 Cr | - | 11.85 Cr | 10.62 Cr | 11.00 Cr | 9.77 Cr | 10.36 Cr | 9.29 Cr |
| Pretax Income | 49.00 Cr | 53.15 Cr | 51.06 Cr | - | 72.00 Cr | 90.59 Cr | 98.69 Cr | 110.37 Cr |
| Tax Provision | 14.70 Cr | 15.08 Cr | 14.81 Cr | - | 18.00 Cr | 17.79 Cr | 21.90 Cr | 25.59 Cr |
| Net Income | 34.00 Cr | 38.07 Cr | 36.24 Cr | - | 54.00 Cr | 72.80 Cr | 76.78 Cr | 84.78 Cr |
| Diluted EPS | 2.27 | 2.31 | 2.20 | - | 3.49 | 4.41 | 4.60 | 5.08 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 263.00 Cr | 315.00 Cr | 314.00 Cr | 394.00 Cr | 854.00 Cr | 1,267.10 Cr | 1,731.17 Cr |
| Cost of Revenue | - | - | - | - | - | 391.07 Cr | 584.36 Cr |
| Gross Profit | - | - | - | - | - | 876.04 Cr | 1,146.81 Cr |
| Operating Expenses | 182.00 Cr | 223.00 Cr | 353.00 Cr | 375.00 Cr | 699.00 Cr | 656.33 Cr | 790.74 Cr |
| Operating Income | 63.00 Cr | 63.00 Cr | -73.00 Cr | -18.00 Cr | 116.00 Cr | 219.71 Cr | 356.06 Cr |
| EBITDA | 81.00 Cr | 92.00 Cr | -39.00 Cr | 18.00 Cr | 155.00 Cr | 265.79 Cr | 396.85 Cr |
| Interest Expense | 6.00 Cr | 9.00 Cr | 10.00 Cr | 19.00 Cr | 31.00 Cr | 34.68 Cr | 31.05 Cr |
| Pretax Income | 74.00 Cr | 63.00 Cr | -66.00 Cr | -11.00 Cr | 103.00 Cr | - | 320.53 Cr |
| Tax Provision | 24.42 Cr | 32.13 Cr | -1.32 Cr | -5.83 Cr | 12.36 Cr | - | 73.80 Cr |
| Net Income | 49.00 Cr | 31.00 Cr | -67.00 Cr | -17.00 Cr | 91.00 Cr | - | 246.74 Cr |
| Diluted EPS | 97.46 | 60.53 | -132.39 | -33.31 | 5.98 | - | 15.31 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | 430.00 Cr | 538.00 Cr | 560.00 Cr | 750.00 Cr | 1,109.00 Cr | - | 2,326.71 Cr |
| Current Assets | - | - | - | - | - | - | 1,681.81 Cr |
| Cash & Equivalents | - | - | - | - | - | - | 185.65 Cr |
| Inventory | - | - | - | - | - | - | 728.99 Cr |
| Receivables | - | - | - | - | - | - | 508.71 Cr |
| Total Liabilities | - | - | - | - | - | - | 1,037.89 Cr |
| Current Liabilities | - | - | - | - | - | - | 835.87 Cr |
| Long Term Debt | - | - | - | - | - | - | 143.02 Cr |
| Total Debt | 30.00 Cr | 93.00 Cr | 175.00 Cr | 320.00 Cr | 425.00 Cr | - | 311.01 Cr |
| Total Equity | 340.00 Cr | 374.00 Cr | 305.00 Cr | 286.00 Cr | 385.00 Cr | - | 1,288.82 Cr |
| Shares Outstanding | - | - | - | - | - | - | 16.48 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.00 Cr | 62.00 Cr | -63.00 Cr | -75.00 Cr | 21.00 Cr | - | 205.05 Cr |
| Investing Cash Flow | -84.00 Cr | -46.00 Cr | -46.00 Cr | -32.00 Cr | -68.00 Cr | - | -409.72 Cr |
| Financing Cash Flow | 80.00 Cr | 52.00 Cr | 63.00 Cr | 123.00 Cr | 44.00 Cr | - | 283.07 Cr |
| Capital Expenditure | -59.00 Cr | -72.00 Cr | -54.00 Cr | -44.00 Cr | -56.00 Cr | - | -229.17 Cr |
| Free Cash Flow | -54.00 Cr | -10.00 Cr | -117.00 Cr | -119.00 Cr | -35.00 Cr | - | -24.12 Cr |
| Net Change in Cash | 1.00 Cr | 67.00 Cr | -45.00 Cr | 16.00 Cr | -4.00 Cr | - | 78.39 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 69.1% | 66.2% |
| Operating Margin % | 24.0% | 20.0% | -23.2% | -4.6% | 13.6% | 17.3% | 20.6% |
| Net Margin % | 18.6% | 9.8% | -21.3% | -4.3% | 10.7% | - | 14.3% |
| ROE % | 14.4% | 8.3% | -22.0% | -5.9% | 23.6% | - | 19.1% |
| ROCE % | - | - | - | - | - | - | 23.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RUBICON
Rubicon Organics Inc. (ROMJ.V) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE4yNEE2SnlHdlFJZEJsVndnTFh4YWlEUTNQbkR5OXpOQUxwSWJZWTNMdmV3SGpXUFNWNU1rc0VURmtUYWVOcU9nN3RRODZERGhIRTBpTg?oc=5" target="_blank">Rubicon Organics Inc. (ROMJ.V) Stock Price, News, Quo…
Rubicon Research Limited (RUBICON.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5oY3ZnbnRRT0tPa3JNR1g4b0puYVVBdnpsblJULWtoMlZuekMwb193dUJpNVFDalJ0X1dDWFhuLXFoVGdBZTQ3cTZ0X293SzRWZFBrQTZUTEZZdw?oc=5" target="_blank">Rubicon Research Limited (RUBICON.NS) Stock P…
Rubicon Organics Inc (ROMJF) Stock Price, Trades & News - GuruFocus
<a href="https://news.google.com/rss/articles/CBMijANBVV95cUxPY2dWRUU0UHR2UGgtVUtXbTd6Q0trU1hFYkk5am5fSS1HRTc0XzM3V0ZkNVVkQUY4RGVrOWVNWjY2WHRBNVgzdlFXQkZmQXlkem5fODdWNTBuZUdpSkxFNWdrSmJPOWhoLUhrN2ZVdFJWdkpjOGxnYkRoVUVVV0lpd3JKWmhsazZhci0xd1…
Rubicon Research Limited (RUBICON.BO) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5EU2tmdEtfWkZUTHRfOWtjUEQ0SlkwOGtVY3VsaTRBZDQ2WXVqaVFqbUNsQ2xvQWdPMUhTb3hldXRvOHFTMjBTX1pWLUx6a2JQWWo1U3NiamREQQ?oc=5" target="_blank">Rubicon Research Limited (RUBICON.BO) Stock P…
Rubicon Research Heads 3 Indian Founder Led Growth Stocks - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPeVJGSGE5Q0RPeHk4NTlXS3BpMHYxYkNOS1A4RHV3ZUhmeWk1WHlzX2Y1WTYtVmUtc01MNHB3SVh6aWpHMDAteWdBSWEyOVppOWxiYldVY2kyaGt1T21yaWVKN25wTzNCSy1NUUhaSnFtUENKOG1BVHZVd0RDRDJrR0RlUWNXRWVJRExST3…
Earnings call transcript: Rubicon Water posts FY 2026 loss as stock falls 18% on outlook - Investing.com
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOQzVFMS16VjhkZF92ZzljSEtYSWxJSWN5aEU0YXlNZHBTaTJrV20xdjZrZThBblkyYnVUc2dJcHdUTDQ2cDJMd3FiQV9ZMXNhZTJPNzR5aTluSFhURHNBVlZDNFljZ2FlYTA4UTMwODc5ekUtU1kxRXQwbDhSUk81SHRVMl9QbGpSbTNLeG…
RUBICON — Frequently Asked Questions
What is the current share price of Rubicon Research Limited (RUBICON)?
As of 2026-10-23 04:58 IST, Rubicon Research Limited (RUBICON) trades at ₹1,448.50 on NSE. Its 52-week range is ₹576.69 to ₹1,860.60.
What is the market capitalisation of RUBICON?
Rubicon Research Limited (RUBICON) has a market capitalisation of ₹23,978.34 Cr on NSE.
What is the P/E ratio of RUBICON?
RUBICON trades at a trailing price-to-earnings (P/E) ratio of 83.44. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 19.84.
Does RUBICON pay a dividend?
Rubicon Research Limited (RUBICON) currently offers a dividend yield of 0.10%.
What is the return on equity (ROE) of RUBICON?
RUBICON has a return on equity (ROE) of 19.14%. Its return on capital employed (ROCE) is 23.58%.
Is RUBICON a good stock to buy?
This page provides a data-driven analysis of Rubicon Research Limited (RUBICON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.